Sage Journals: Discover world-class research

Abstract

This article examines the relationship between federal regulations, state scope-of-practice regulations on nurse practitioners (NPs), and buprenorphine prescribing patterns using pharmacy claims data from Optum’s deidentified Clinformatics Data Mart between January 2015 and September 2018. The county-level proportion of patients filling prescriptions written by NPs was low even after the 2016 Comprehensive Addiction and Recovery Act (CARA), 2.7% in states that did not require physician oversight of NPs, and 1.1% in states that did. While analyses in rural counties showed higher rates of buprenorphine prescriptions written by NPs, rates were still considerably low: 3.7% in states with less restrictive regulations and 1.1% in other states. These results indicate that less restrictive scope-of-practice regulations are associated with greater NP prescribing following CARA. The small magnitude of the changes indicates that federal attempts to expand treatment access through CARA have been limited.

Keywords

buprenorphine prescribing nurse practitioners scope-of-practice regulations Comprehensive Addiction and Recovery Act

Get full access to this article

View all access options for this article.

References

Andraka-Christou

Capone

M. J.

(2018). A qualitative study comparing physician-reported barriers to treating addiction using buprenorphine and extended-release naltrexone in U.S. office-based practices. International Journal of Drug Policy, 54(April), 9–17. https://doi.org/10.1016/j.drugpo.2017.11.021

Andrilla

C. H. A.

Moore

T. E.

Patterson

D. G.

Larson

E. H.

(2018). Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: A 5-year update. Journal of Rural Health, 35(1), 108–112. https://doi.org/10.1111/jrh.12307

Andrilla

C. H. A.

Patterson

D. G.

Moore

T. E.

Coulthard

Larson

E. H.

(2018). Projected contributions of nurse practitioners and physicians assistants to buprenorphine treatment services for opioid use disorder in rural areas. Medical Care Research and Review, 77(2), 208–216. https://doi.org/10.1177/1077558718793070.

Auty

S. G.

Stein

M. D.

Walley

A. Y.

Drainoni

M.-L.

(2020). Buprenorphine waiver uptake among nurse practitioners and physician assistants: The role of existing waivered prescriber supply. Journal of Substance Abuse Treatment, 115, 108032. https://doi.org/10.1016/j.jsat.2020.108032

Bain

Wong

C. A.

Slap

Polsky

Merchant

R. M.

Antwi

Y. A.

Rubin

Ford

C. A.

(2016). Common and costly hospitalizations among insured young adults since the Affordable Care Act. Journal of Adolescent Health, 59(1), 61–67. https://doi.org/10.1016/j.jadohealth.2016.03.013

Barnett

M. L.

Lee

Frank

R. G.

(2019). In rural areas, buprenorphine waiver adoption since 2017 driven by nurse practitioners and physician assistants. Health Affairs, 38(12), 2048–2056. https://doi.org/10.1377/hlthaff.2019.00859

Centers for Disease Control and Prevention. (2018). CDC compilation of benzodiazepines, muscle relaxants, stimulants, zolpidem, and opioid analgesics with oral morphine milligram equivalent conversion factors, 2018 version. https://www.cdc.gov/drugoverdose/resources/data.html

Centers for Disease Control and Prevention, National Center for Health Statistics. (2017). NCHS urban-rural classification scheme for counties. https://www.cdc.gov/nchs/data_access/urban_rural.htm

Diamond

(2021, January 27). Biden kills Trump plan on opioid-treatment prescriptions. The Washington Post. https://www.washingtonpost.com/health/2021/01/27/biden-kills-buprenorphine-waiver/

10.

Fiscella

Wakeman

S. E.

Beletsky

(2019). Buprenorphine deregulation and mainstreaming treatment for opioid use disorder: X the X waiver. JAMA Psychiatry, 76(3), 229–230. https://doi.org/10.1001/jamapsychiatry.2018.3685

11.

Gordon

A. J.

Kavanagh

Krumm

Ramgopal

Paidisetty

Aghevli

Goodman

Trafton

Liberto

(2011). Facilitators and barriers in implementing buprenorphine in the Veterans Health Administration. Psychology of Addictive Behaviors, 25(2), 215–224. https://doi.org/10.1037/a0022776

12.

Haffajee

R. L.

Andraka-Christou

B. A.

Foney

D. M.

Beck

A. J.

Page

Buche

M. P. P. J

. (2018). Nurse practitioner and physician assistant provision of medication-assisted treatment for opioid use disorder: a survey of knowledge, engagement, and perceptions. University of Michigan Behavioral Health Workforce Research Center.

13.

Haffajee

R. L.

Bohnert

A. S. B.

Lagisetty

P. A.

(2018). Policy pathways to address provider workforce barriers to buprenorphine treatment. American Journal of Preventive Medicine, 54(6), S230–S242. https://doi.org/10.1016/j.amepre.2017.12.022

14.

Henry

(2015). Experiences and attitudes of primary care providers under the first year of ACA coverage expansion: Findings from the Kaiser Family Foundation/Commonwealth Fund 2015 National Survey of Primary Care Providers. Issue Brief (Commonwealth Fund), 17, 1.

15.

Huskamp

H. A.

Busch

A. B.

Uscher-Pines

Barnett

M. L.

Riedel

Mehrotra

(2020). Treatment of opioid use disorder among commercially insured patients in the context of the COVID-19 pandemic. Journal of the American Medical Association, 324(23), 2440–2442. https://doi.org/10.1001/jama.2020.21512

16.

Illinois Society for Advanced Practice Nursing. (2018, January 8). Update on Nurse Practice Act: APRN full practice authority. https://www.isapn.org/news/381212/Update-on-Nurse-Practice-Act—APRN-Full-Practice-Authority.htm

17.

Jones

C. M.

Campopiano

Baldwin

McCance-Katz

(2015). National and state treatment need and capacity for opioid agonist medication-assisted treatment. American Journal of Public Health, 105(8), e55–e63. https://doi.org/10.2105/AJPH.2015.302664

18.

Jones

C. M.

McCance-Katz

E. F.

(2019). Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder. Addiction, 114(3), 471–482. https://doi.org/10.1111/add.14436

19.

Larochelle

M. R.

Bernson

Land

Stopka

T. J.

Wang

Xuan

Bagley

S. M.

Liebschutz

J. M.

Walley

A. Y.

(2018). Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A cohort study. Annals of Internal Medicine, 169(3), 137–145. https://doi.org/10.7326/M17-3107

20.

Ling

(2012). Buprenorphine implant for opioid addiction. Pain Management, 2(4), 345–350. https://doi.org/10.2217/pmt.12.26

21.

Magidson

J. F.

Jack

H. E.

Regenauer

K. S.

Myers

(2019). Applying lessons from task sharing in global mental health to the opioid crisis. Journal of Consulting and Clinical Psychology, 87(10), 962–966. https://doi.org/10.1037/ccp0000434

22.

Moore

D. J.

(2019). Nurse practitioners’ pivotal role in ending the opioid epidemic. Journal for Nurse Practitioners, 15(5), 323–327. https://doi.org/10.1016/j.nurpra.2019.01.005

23.

Nguyen

T. D.

Andraka-Christou

Simon

Bradford

W. D.

(2019). Comparison of rural vs urban direct-to-physician commercial promotion of medications for treating opioid use disorder. JAMA Network Open, 2(12), e1916520–e1916520. https://doi.org/10.1001/jamanetworkopen.2019.16520

24.

Nguyen

T. D.

Gupta

Ziedan

Simon

K. I.

Alexander

G. C.

Saloner

Stein

(2020). Assessment of filled buprenorphine prescriptions for opioid use disorder during the coronavirus disease 2019 pandemic. JAMA Internal Medicine, 324. https://doi.org/10.1001/jamainternmed.2020.7497

25.

Olfson

Zhang

V. S.

Schoenbaum

King

(2020). Trends in buprenorphine treatment in the United States, 2009-2018. Journal of the American Medical Association, 323(3), 276–277. https://doi.org/10.1001/jama.2019.18913

26.

Ramey

J. A.

(2016). U.S. census regional and demographic data. https://cran.r-project.org/web/packages/noncensus/noncensus.pdf

27.

Roehler

D. R.

Guy

G. P.

Jr Jones

C. M.

(2020). Buprenorphine prescription dispensing rates and characteristics following federal changes in prescribing policy, 2017-2018: A cross-sectional study. Drug and Alcohol Dependence, 213, Article 108083. https://doi.org/10.1016/j.drugalcdep2020.108083

28.

Saloner

Karthikeyan

(2015). Changes in substance abuse treatment use among individuals with opioid use disorders in the United States, 2004-2013. Journal of the American Medical Association, 314(14), 1515–1517. https://doi.org/10.1001/jama.2015.10345

29.

Spetz

(2019). California’s nurse practitioners: How scope of practice laws impact care. https://www.chcf.org/wp-content/uploads/2018/09/NursePractitionerScopePracticeLaws.pdf

30.

Spetz

Toretsky

Chapman

Phoenix

Tierney

(2019). Nurse practitioner and physician assistant waivers to prescribe buprenorphine and state scope of practice restrictions. JAMA Journal of the American Medical Association, 321(14), 1407–1408. https://doi.org/10.1001/jama.2019.0834

31.

Theken

K. N.

(2018). Variability in analgesic response to non-steroidal anti-inflammatory drugs. Prostaglandins & Other Lipid Mediators, 139(November), 63–70. https://doi.org/10.1016/j.prostaglandins.2018.10.005

32.

The SUPPORT for Patients and Communities Act. (2018). https://www.congress.gov/bill/115th-congress/house-bill/6

33.

Wakeman

S. E.

Larochelle

M. R.

Ameli

Chaisson

C. E.

McPheeters

J. T.

Crown

W. H.

Azocar

Sanghavi

D. M.

(2020). Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Network Open, 3(2), e1920622. https://doi.org/10.1001/jamanetworkopen.2019.20622

The Association Between Scope of Practice Regulations and Nurse Practitioner Prescribing of Buprenorphine After the 2016 Opioid Bill

Abstract

Keywords

Get full access to this article

References